194 related articles for article (PubMed ID: 10888033)
1. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
[TBL] [Abstract][Full Text] [Related]
2. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
[TBL] [Abstract][Full Text] [Related]
3. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
4. The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies.
Saishin Y; Saishin Y; Takahashi K; Seo MS; Melia M; Campochiaro PA
Invest Ophthalmol Vis Sci; 2003 Aug; 44(8):3656-62. PubMed ID: 12882820
[TBL] [Abstract][Full Text] [Related]
5. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.
Fabbro D; Buchdunger E; Wood J; Mestan J; Hofmann F; Ferrari S; Mett H; O'Reilly T; Meyer T
Pharmacol Ther; 1999; 82(2-3):293-301. PubMed ID: 10454207
[TBL] [Abstract][Full Text] [Related]
7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
8. Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice.
Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Anticancer Res; 2003; 23(2B):1395-9. PubMed ID: 12820400
[TBL] [Abstract][Full Text] [Related]
9. Effect of PKC412, a selective inhibitor of protein kinase C, on lung metastasis in mice injected with B16 melanoma cells.
Yoshikawa N; Nakamura K; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Life Sci; 2003 Feb; 72(12):1377-87. PubMed ID: 12527035
[TBL] [Abstract][Full Text] [Related]
10. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
12. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K
Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PKCalpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412.
Kawamoto T; Akisue T; Kishimoto K; Hara H; Imabori M; Fujimoto T; Kurosaka M; Hitora T; Kawaguchi Y; Yamamoto T
Anticancer Res; 2008; 28(2A):825-32. PubMed ID: 18507025
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier.
Saishin Y; Saishin Y; Takahashi K; Melia M; Vinores SA; Campochiaro PA
J Cell Physiol; 2003 May; 195(2):210-9. PubMed ID: 12652648
[TBL] [Abstract][Full Text] [Related]
19. PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts.
Nakazono-Kusaba A; Takahashi-Yanaga F; Miwa Y; Morimoto S; Furue M; Sasaguri T
Eur J Pharmacol; 2004 Aug; 497(2):155-60. PubMed ID: 15306200
[TBL] [Abstract][Full Text] [Related]
20. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
Ozaki H; Seo MS; Ozaki K; Yamada H; Yamada E; Okamoto N; Hofmann F; Wood JM; Campochiaro PA
Am J Pathol; 2000 Feb; 156(2):697-707. PubMed ID: 10666398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
